These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23281497)

  • 1. The limits of free speech.
    Nature; 2012 Dec; 492(7429):311. PubMed ID: 23281497
    [No Abstract]   [Full Text] [Related]  

  • 2. Off-label or off-limits?
    Ratner M; Gura T
    Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
    [No Abstract]   [Full Text] [Related]  

  • 3. Off-label marketing and the First Amendment.
    Boumil MM
    N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
    [No Abstract]   [Full Text] [Related]  

  • 4. Free speech rights outweigh restrictions on promoting drugs off label, court rules.
    Roehr B
    BMJ; 2012 Dec; 345():e8324. PubMed ID: 23220261
    [No Abstract]   [Full Text] [Related]  

  • 5. Off-label marketing: free speech or illegal promotion?
    Silverman E
    BMJ; 2013 Jan; 346():f320. PubMed ID: 23341546
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA regulation of off-label drug promotion under attack.
    Kesselheim AS; Mello MM; Avorn J
    JAMA; 2013 Feb; 309(5):445-6. PubMed ID: 23385267
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical trial transparency--antidote to weaker off-label-promotion rules?
    Outterson K
    N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
    [No Abstract]   [Full Text] [Related]  

  • 8. Company pays over $81m for allegedly promoting topiramate for unapproved uses.
    Kmietowicz Z
    BMJ; 2010 May; 340():c2848. PubMed ID: 20508021
    [No Abstract]   [Full Text] [Related]  

  • 9. When true enough is not good enough.
    Nat Med; 2013 Jan; 19(1):1. PubMed ID: 23295988
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulating Off-Label Promotion - A Critical Test.
    Robertson C; Kesselheim AS
    N Engl J Med; 2016 Dec; 375(24):2313-2315. PubMed ID: 27805841
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

  • 12. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 13. Court rules that FDA cannot restrict off-label marketing.
    Roehr B
    BMJ; 2015 Aug; 351():h4367. PubMed ID: 26265632
    [No Abstract]   [Full Text] [Related]  

  • 14. Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.
    Kalb PE; Greenberg PE
    Pharmacoeconomics; 2009; 27(8):623-5. PubMed ID: 19835018
    [No Abstract]   [Full Text] [Related]  

  • 15. The strange allure of state "right-to-try" laws.
    Zettler PJ; Greely HT
    JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589
    [No Abstract]   [Full Text] [Related]  

  • 16. Pfizer settles largest ever fraud suit for off-label promotion.
    Ratner M
    Nat Biotechnol; 2009 Nov; 27(11):961-2. PubMed ID: 19898429
    [No Abstract]   [Full Text] [Related]  

  • 17. Defining "True and Non-Misleading" for Pharmaceutical Promotion.
    Hey SP; Kesselheim AS
    J Law Med Ethics; 2018 Jun; 46(2):552-554. PubMed ID: 30146990
    [No Abstract]   [Full Text] [Related]  

  • 18. Marketing of antipsychotic drugs targeted doctors of Medicaid patients, report says.
    Roehr B
    BMJ; 2012 Oct; 345():e6633. PubMed ID: 23033376
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug manufacturers' First Amendment right to advertise and promote their products for off-label use: avoiding a pyrrhic victory.
    Blackwell AE; Beck JM;
    Food Drug Law J; 2003; 58(3):439-62. PubMed ID: 14626985
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.